Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE versus RASUVO.
METHOTREXATE vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate antimetabolite; inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate (DHF) to tetrahydrofolate (THF), thereby inhibiting DNA synthesis, repair, and cellular replication. Also inhibits thymidylate synthetase and purine synthesis.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
7.5-25 mg orally once weekly; alternatively, 10-25 mg intramuscularly, intravenously, or subcutaneously once weekly.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
Clinical Note
moderateMethotrexate + Digoxin
"Methotrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethotrexate + Digitoxin
"Methotrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethotrexate + Deslanoside
"Methotrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethotrexate + Acetyldigitoxin
"Methotrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3-10 hours (low dose) to 8-15 hours (high dose); clinical context: prolonged to 24-48 hours in renal impairment, third-space effusions, or polyglutamation. Delayed elimination due to enterohepatic recirculation.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <10% as metabolites (7-hydroxymethotrexate).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category D/X
Category C
Antimetabolite
Antimetabolite